tbuckley/cabot-search huggingface dataset:
Inhibition of Purified DNA Polymerase of RNA Tumor Viruses by Fluoranthene Derivatives and Analogues of Tilorone Hydrochloride&lt;xref ref-type="fn" rid="fn2"&gt;2&lt;/xref&gt;
Authors: Green, Maurice, Rankin, Anne, Gerard, Gary F., Grandgenett, Duane P., Green, Michael R.
Journal: JNCI Journal of the National Cancer Institute (1975)

Journal Article Inhibition of Purified DNA Polymerase of RNA Tumor Viruses by Fluoranthene Derivatives and Analogues of Tilorone Hydrochloride Get access Maurice Green, Maurice Green Search for other works by this author on: Oxford Academic PubMed Google Scholar Anne Rankin, Anne Rankin Search for other works by this author on: Oxford Academic PubMed Google Scholar Gary F. Gerard, Gary F. Gerard Search for other works by this author on: Oxford Academic PubMed Google Scholar Duane P. Grandgenett, Duane P. Grandgenett Search for other works by this author on: Oxford Academic PubMed Google Scholar Michael R. Green Michael R. Green Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 55, Issue 2, August 1975, Pages 433–442, https://doi.org/10.1093/jnci/55.2.433 Published: 01 August 1975 Article history Received: 21 January 1975 Accepted: 11 April 1975 Published: 01 August 1975
Booster Doses of Influenza Vaccine
Authors: Kristin L. Nichol
Journal: JAMA (1996)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Multiple Risk Factor Intervention Trial (MRFIT)
Journal: JAMA (1976)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Current Procedural Terminology (CPT)
Journal: JAMA (1970)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Induction of Gastric Carcinomas in Nonhuman Primates by &lt;italic&gt;N&lt;/italic&gt;-Ethyl-&lt;italic&gt;N′&lt;/italic&gt;-Nitro-&lt;italic&gt;N&lt;/italic&gt;-Nitrosoguanidine&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;
Journal: JNCI Journal of the National Cancer Institute (1986)

N-Ethyl-N′-nitro-N-nitrosoguanidine [(ENNG) CAS: 63885-23-4] was administered to 5 Macaca monkeys (Macaca mulatta and M. irus) at a concentration of 200 or 300 µg/ml for 11–26 months in their drinking water. Gastric carcinomas in the pyloric region were observed in ailS monkeys between experimental months 11 and 38. Histologically, these carcinomas were mainly poorly differentiated aoenoearcmornas and signet-ring cell carcinomas, and a few moderately and well-differentiated adenocarcinomas were also found. The macroscopic and histologic appearances of these carcinomas were similar to those in humans.
Carcinogen-Induced DNA Damage and Cellular Alterations in F344 Rat Colon Organ Cultures&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;&lt;xref ref-type="fn" rid="FN3"&gt;3&lt;/xref&gt;
Authors: Telang, Nitin T., Williams, Gary M.
Journal: JNCI Journal of the National Cancer Institute (1982)

Journal Article Carcinogen-Induced DNA Damage and Cellular Alterations in F344 Rat Colon Organ Cultures Get access Nitin T. Telang, Nitin T. Telang Search for other works by this author on: Oxford Academic PubMed Google Scholar Gary M. Williams Gary M. Williams 6 6Address reprint requests to Dr. Williams. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 68, Issue 6, June 1982, Pages 1015–1022, https://doi.org/10.1093/jnci/68.6.1015 Published: 01 June 1982 Article history Received: 04 September 1981 Accepted: 26 January 1982 Published: 01 June 1982
Failure to Diagnose Acute Myocardial Infarction
Authors: Edwin J. Zarling
Journal: JAMA (1983)

A retrospective study of 100 consecutive cases of autopsy-proved acute myocardial infarction has disclosed a surprisingly low frequency (53%) of correct antemortem diagnoses. Incorrect diagnoses seemed to be caused by (1) unjustified dependence on misleading laboratory studies, (2) inattention to suggestive or diagnostic laboratory studies, (3) atypical or obscure presentation of myocardial infarction, and (4) failure to consider acute myocardial infarction as a diagnostic possibility, particularly when the responsible physician was not a specialist in internal medicine or its subspecialty of cardiology. Suggested corrective measures are a more appropriate use of the ECG and the laboratory and education and reeducation of selected groups of physicians. (<i>JAMA</i>1983;250:1177-1181)
Cyclosporine, in Combination With Other Drugs, Studied in Insulin-Dependent Diabetes Therapy
Authors: Chris Anne Raymond
Journal: JAMA (1988)

CYCLOSPORINE TRIALS in persons with insulin-dependent diabetes mellitus (IDDM) offer both good news and bad. The good news is that the results have cinched the role of autoimmune responses in the disease's pathophysiology, opening the way for better combined immunotherapies. The bad news is that the drug, at least as it is now being used, offers at most an extended honeymoon from insulin dependence. But when cyclosporine therapy is withdrawn, the honeymoon is over. In recent months, clinical investigators from around the world have been reporting the results of controlled trials of cyclosporine in patients with recent-onset IDDM. At such meetings as the 35th postgraduate course of the American Diabetes Association in Palm Desert, Calif, the Research and Clinical Frontiers of Diabetes meeting in St Louis, and the American Diabetes Association scientific session in Indianapolis, discussion of the results has centered on weighing the potential risks against the benefits. "With
The Rat in Laboratory Investigation
Journal: JAMA (1942)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Materia Medica and Therapeutics: A Text-Book for Nurses.
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Response of the RIF-1 Tumor In Vitro and in C3H/Km Mice to X-Radiation (Cell Survival, Regrowth Delay, and Tumor Control), Chemotherapeutic Agents, and Activated Macrophages&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;&lt;xref ref-type="fn" rid="FN3"&gt;3&lt;/xref&gt;
Journal: JNCI Journal of the National Cancer Institute (1980)

Journal Article Response of the RIF-1 Tumor In Vitro and in C3H/Km Mice to X-Radiation (Cell Survival, Regrowth Delay, and Tumor Control), Chemotherapeutic Agents, and Activated Macrophages Get access J. Martin Brown, J. Martin Brown 4Division of Radiobiology Research, Department of Radiology, Stanford University School of Medicine, Stanford, Calif. 94305. Search for other works by this author on: Oxford Academic PubMed Google Scholar Peter R. Twentyman, Peter R. Twentyman 4Division of Radiobiology Research, Department of Radiology, Stanford University School of Medicine, Stanford, Calif. 94305. Search for other works by this author on: Oxford Academic PubMed Google Scholar Scott S. Zamvil Scott S. Zamvil 4Division of Radiobiology Research, Department of Radiology, Stanford University School of Medicine, Stanford, Calif. 94305. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 64, Issue 3, March 1980, Pages 605–611, https://doi.org/10.1093/jnci/64.3.605 Published: 01 March 1980 Article history Received: 19 April 1979 Accepted: 27 July 1979 Published: 01 March 1980
Is Institute of Medicine the Agency to Lead Science's Attack on AIDS?
Authors: Charles Marwick
Journal: JAMA (1987)

KNOWLEDGE of the acquired immunodeficiency syndrome (AIDS) virus (human immunodeficiency virus [HIV]), its structure, and the way it replicates is now sufficient for development of drugs to prevent or inhibit HIV replication and prevent infection in high-risk groups. At the same time, a national effort is needed to bring government, academia, and industry together to accomplish this. This was the main message from a two-day meeting held by the Institute of Medicine (IOM), Washington, DC, and devoted to discussion of drugs against AIDS. Information accumulated about HIV indicates there are a variety of targets for antiviral drugs, each of which is worthy of a large research effort, notes William Haseltine, MD, Dana-Farber Cancer Center, Boston. Nevertheless, he adds, "The development of anti-HIV drugs is not going to be simply a matter of applying this knowledge. A large segment of this problem lies in the unknown." "There are surprises in store,
The Robert Wood Johnson Health Policy Fellowship
Authors: Charles M. Helms
Journal: JAMA (1988)

IN JANUARY, as the federal legislative process reawakens with renewed vigor on Capitol Hill with the full attention of the national media, another process is concluding quietly in northwest Washington, DC. A board that consists of nationally recognized experts in the health sciences, political science, and public policy completes its annual charge of selecting six Robert Wood Johnson (RWJ) Health Policy Fellows. These RWJ fellows, faculty members from health-related professional schools, will be granted leave from their academic institutions to come to Washington, DC, for a year of intensive study. They will receive a special invitation to what Woodrow Wilson originally described and Eric Redman popularized as "the dance of legislation." <h3>THE RWJ HEALTH POLICY FELLOWSHIP PROGRAM</h3> The RWJ Health Policy Fellowship Program was initiated in 1973. Funded by the Robert Wood Johnson Foundation, Princeton, NJ, and administered by the Institute of Medicine, Washington, DC, the fellowships provide midcareer academic
Hemorrhage From Transrectal Needle Biopsy of Prostate
Authors: Jack E. Mobley
Journal: JAMA (1971)

<h3>To the Editor.—</h3> Needle biopsy of the prostate has become a widely used and almost universally accepted diagnostic procedure. In 1967, Wendell and Evans noted that during the preceding 30 years, 4,300 biopsies had been reported with a complication rate of 3.7%.<sup>1</sup>No fatalities had been recorded. In their own 250 patients, a complication rate of 7% included two patients with rather large retropubic hematomas. The bleeding complications of prostatic needle biopsy, hematuria, hemospermia, rectal bleeding, perineal hematoma, or retropubic hematoma, have almost never required surgical intervention.<sup>2-5</sup> A patient at the University of Arkansas Medical Center recently had an episode of bleeding requiring emergency surgical treatment following a transrectal needle biopsy of the prostate. <h3>Report of a Case.—</h3> An 86-year-old Negro man was seen Feb 22, 1971, with symptoms of lower urinary tract obstruction. He had suffered a "stroke" six months earlier with complete recovery. He had noticed
A Deletion in Chromosome 1 in Cells of a Transplantable Granulocytic Leukemia (GL-13) in Guinea Pigs&lt;xref ref-type="fn" rid="fn2"&gt;2&lt;/xref&gt;
Authors: Dorothy E. Moore
 4, Warren H. Evans, Michael G. Mage
Journal: JNCI Journal of the National Cancer Institute (1982)

Chromosomes were examined in leukocytes from a unique transplantable granulocytic leukemia (GL-13) of strain 13 guinea pigs. The GL-13 leukemia has many similarities to human chronic myelogenous leukemia (CML). It has remained predominantly diploid after 90 transplant generations and is characterized cytogenetically by a terminal deletion of the long arm of one of the #1 pair of chromosomes. No other chromosomal abnormality was observed. These findings lend further support to the conclusion that the GL-13 leukemia may be a useful model for the study of human CML.
Chromosomes and Cloning Efficiencies of Hematopoietic Cell Lines Derived From Patients With Leukemia, Melanoma, Myeloma, and Burkitt Lymphoma&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Journal: JNCI Journal of the National Cancer Institute (1969)

The chromosomes and cloning efficiencies of 9 hematopoietic cell lines derived from the blood of patients with myelogenous leukemia (3 lines), malignant melanoma (1 line), and myeloma (2 lines), and from biopsies of Burkitt lymphoma (3 lines), were studied. The melanoma line, the only one with a diploid mode, had the lowest cloning efficiency, 5.3%, with no macroscopic colonies. The chromosome modes of 3 leukemic lines, 1 myeloma line, and 3 Burkitt lines were either pseudodiploid or hyperdiploid. The cloning efficiencies of the 3 leukemic lines and 1 myeloma line ranged from 12–35%, including only a few macroscopic colonies, whereas the 3 Burkitt lines ranged from 11–81%, all macroscopic. The other myeloma line had a bimodal chromosome distribution (hypodiploid and hypertriploid) when first examined; in later examinations, it had changed to a hypotriploid mode. Cloning efficiency of this line was 51%, all macroscopic colonies. The data indicated that chromosome constitution and cloning efficiency, together with ability to grow in heterologous hosts, are valid indicators for evaluating cell normalcy or malignancy in human hematopoietic cell lines. The chromosomes of 20 cloned sublines derived from 2 leukemic lines and 2 Burkitt lines were analyzed. The chromosome constitutions of the sublines derived from 2 leukemic lines and 1 Burkitt line were similar to the parental lines, whereas cloned sublines of the other Burkitt line (P3J, 2n = 47) had modal chromosome numbers of 47, 48, and 49, and cloning efficiencies much lower than those of the parental line. Chromosome pulverization was observed in 1 myeloma line and 1 cloned subline of P3J.
Patterns of matrix metalloproteinase and TIMP-1 expression in chronic and normally healing human cutaneous wounds
Authors: M. VAALAMO, M. WECKROTH, P. PUOLAKKAINEN, J. KERE, P. SAARINEN, J. LAUHARANTA, U.K. SAARIALHO-KERE
Journal: British Journal of Dermatology (1996)

The present study was carried out to characterize the patterns of expression of matrix metalloproteinases or their tissue inhibitor (TIMP‐1) in normally healing, acute vs. chronic, skin wounds. In situ hybridization was performed to localize collagenase, stromelysin‐1, stromelysin‐2, matrilysin, urokinase plasminogen activator (uPA) and TIMP‐1 mRNAs in 14 chronic venous ulcers and 10 normally healing wounds, representing different time points after wounding. Surgical wounds, made in piglets harvested at several time points, were studied as controls. Collagenase, stromelysin‐1 and ‐2, as well as uPa, were expressed in keratinocytes in both acute and chronic wounds, while epithelial TIMP‐1 mRNA was not detected in any chronic wound biopsies studied. However, TIMP‐1 was expressed at the epithelial edges of both acute human and pig wounds. Our results suggest that the balance between metalloenzymes and their inhibitor TIMP‐1, is disturbed, in poorly healing wounds.
Reply
Journal: Clinical Cancer Research (2004)

Tsiridis et al. presented an unusual case of avascular necrosis in the peripheral bone, which was later found to be combined with a glioblastoma in the brain. They suspected the avascular necrosis was caused by an endogenous inhibitor of angiogenesis, such as endostatin or transforming growth factor β, secreted from the glioblastoma tissue. Their hypothesis is very attractive. However, it is necessary to show data supporting a direct causal relationship between a glioblastoma and avascular necrosis of the peripheral bone. Detection of the tissue levels or serum levels of endostatin or transforming growth factor β could support the hypothesis. Although we showed increased levels of tissue endostatin in glioblastomas (1), we unfortunately did not examine the levels of endostatin in the serum for these patients. Furthermore, there have been no reports in which glioblastomas or other tumors secreting high levels of endostatin are combined with avascular necrosis of the peripheral bone (2, 3). With regard to the systemic effects of antiangiogenic therapies suggested by Tsiridis et al., no side effects such as avascular necrosis of the peripheral bone have been reported in a Phase I clinical trial of recombinant endostatin (4). However, this case report by Tsiridis et al. will promote further careful survey for the systemic effects of antiangiogenic factors in tumors secreting high levels of endostatin as well as in clinical application of recombinant endostatin.
Diseases of the Eye. A Handbook of Ophthalmic Practice for Students and Practitioners.
Journal: JAMA (1924)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Tropical medicine in and out of the tropics
Authors: D.J. Weatherall, DavidA.K. Watters, Surinder Kaul, DavidA. Warrell, NicholasJ. White, François Nosten, Nicholas Day, David Mabey, KevinM. De Cock, SebastianB. Lucas, Eldryd Parry, Paul Garner, Ayyaz Kiani, Rodrigo Salinas, Joost Zaat, Marc De Bruycker, Paul Hagan, Michel Pletschette, Elil Renganathan, Mohammad Ramadan, Giovanni Rocchi
Journal: The Lancet (1996)